Developer docs
API playgroundTry for free, no card

Search company profiles

Nouscom

Full company profile

uuid00041sk

Namestring
Nouscom
Legal namestring
Nouscom AG
Websiteurl
nouscom.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad and potent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity.

Short descriptiontext

Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, viral vector vaccines, neoantigen vaccines, immuno-oncology biotech, oncolytic virus therapy
Industry3 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Cancer Immunotherapy Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing next-generation immunotherapies. Revenue will be generated through commercialization of approved cancer immunotherapies (NOUS-209, NOUS-PEV) upon successful clinical development and regulatory approval.

nouscom.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NOUS-209
Description

Off-the-shelf cancer immunotherapy encoding 209 shared frameshift peptide neoantigens for treatment of dMMR/MSI tumors and cancer interception in Lynch Syndrome carriers

nouscom.com
+3 more records
Core offering1 text field

Nouscom develops next-generation viral vectored cancer immunotherapies based on a proprietary heterologous prime/boost platform using Great Ape Adenovirus (GAd) and Modified Vaccinia Virus Ankara (MVA). Its clinical candidates include NOUS-209 (off-the-shelf immunotherapy for MSI-H/dMMR tumors and Lynch Syndrome cancer interception), NOUS-PEV (personalized neoantigen vaccine for solid tumors), and NOUS-THV-001 (targeted and armored oncolytic herpes virus), supported by the proprietary VENUS neoantigen prediction algorithm.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% of evaluable participants (37/37) developed robust T cell responses against multiple neoantigens in Lynch Syndrome trial
+4 more records
Product overview1 text field

Nouscom is a clinical-stage biotech company developing next-generation cancer immunotherapies based on proprietary viral vector platforms. The company's portfolio consists of three main products: NOUS-209 (an off-the-shelf immunotherapy encoding 209 shared neoantigens for MSI tumors and Lynch Syndrome cancer interception), NOUS-PEV (a personalized neoantigen vaccine tailored to individual patient tumors using the VENUS algorithm), and NOUS-THV-001 (an armored oncolytic herpes virus for solid tumors). The technology platform combines great ape adenovirus (GAd) and Modified Vaccinia Virus Ankara (MVA) vectors with bioinformatics tools for neoantigen prediction. Clinical programs span from early cancer interception in Lynch Syndrome carriers to treatment of metastatic colorectal cancer.

Product and service1 record
1NOUS-209
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1MD Anderson Cancer Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MD Anderson Cancer Center serves as the principal investigator site for the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome carriers (NCT05078866). The trial is conducted through the iCAN-PREVENT consortium. Dr. Eduardo Vilar-Sanchez is the principal investigator.

nouscom.com
2National Cancer Institute (NCI)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The NCI, part of the National Institutes of Health, sponsors clinical trial NCT05078866 under Award Number UG1CA242609. Activities are coordinated through the iCAN-PREVENT consortium.

nouscom.com
3Leuven Cancer Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Leuven Cancer Institute in Belgium served as principal investigator site for the Phase 1b trial of NOUS-PEV in solid tumors. Dr. Oliver Bechter is the principal investigator.

nouscom.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1BioNTech
TypeDirect peer
Description

Global leader in personalized neoantigen cancer vaccines (e.g., BNT122/RO7198457 with Roche) using mRNA platform. Directly comparable to Nouscom in target biology (personalized neoantigens, MSI/solid tumors) and combination-with-checkpoint-inhibitor strategy, though using a different delivery modality.

2Moderna
TypeDirect peer
Description

Develops mRNA-4157, a personalized neoantigen cancer vaccine in Phase 3 with Merck (KEYNOTE-942). Competes head-to-head with NOUS-PEV in melanoma/NSCLC combination settings with pembrolizumab and is the dominant scale competitor in personalized cancer vaccines.

3Gritstone bio
TypeDirect peer
Description

Develops shared-neoantigen (off-the-shelf, e.g., SLATE) and personalized (autogene cevumeran with Roche) neoantigen cancer vaccines. Highly comparable technology overlap with NOUS-209 (shared FSP antigens) and NOUS-PEV (personalized), targeting similar MSI and solid tumor indications.

4Transgene
TypeDirect peer
Description

French clinical-stage biotech using viral vector (MVA, vaccinia, adenovirus) platforms for cancer immunotherapy, including oncolytic viruses and therapeutic vaccines. Closest direct competitor in terms of viral vector delivery technology and immuno-oncology focus.

5Bavarian Nordic
TypeDirect peer
Description

MVA-based vaccine specialist (MVA-BN platform, JYNNEOS) now expanding into cancer immunotherapy combinations. Comparable in viral vector backbone (MVA) and potential overlap with NOUS-209 prime-boost constructs.

6CureVac
TypeDirect peer
Description

mRNA-based cancer vaccine developer (CV8102, CV9202) with ongoing oncology programs in combination with checkpoint inhibitors and shared antigen approaches. Comparable personalized cancer vaccine peer using a different delivery platform.

7Merck KGaA
TypeBroad incumbent
Description

Operates a viral vector / MVA manufacturing platform through its Life Science and Healthcare divisions and is a major checkpoint inhibitor (avelumab) provider often used in combinations. Comparable on viral vector CMC capabilities and combination immuno-oncology positioning.

8ISA Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biotech developing synthetic long peptide therapeutic cancer vaccines (e.g., ISA101b HPV) with checkpoint combinations. Directly comparable therapeutic vaccine modality targeting defined tumor antigens.

9PsiOxus Therapeutics
TypeDirect peer
Description

Develops oncolytic virus platforms (e.g., enadenotucirev, NG-641) with immune-armoring for solid tumors. Closely comparable to NOUS-THV-001 in the oncolytic virus / TME-modulation space.

10Amgen (Imlygic / BioVex legacy)
TypeBroad incumbent
Description

Through Imlygic (talimogene laherparepvec), Amgen commercializes the only FDA-approved oncolytic HSV. Comparable in oncolytic herpes virus technology and armored immunomodulation strategy to NOUS-THV-001, though serving an established melanoma indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nouscom

Cancer Immunotherapynouscom.com

Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.

What Nouscom does

Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized for the efficient expression of long strings of tumor neoantigens. It also includes a toolkit for inducing broad and potent antitumor T-cell responses, allowing patients to boost cancer-specific cellular immunity.

Nouscom firmographics

Firmographics
Name
Nouscom
Legal name
Nouscom AG
Website
https://nouscom.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.
Ownership category
akta.pro rank

Nouscom industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Cancer immunotherapy
  • Viral vector vaccines
  • Neoantigen vaccines
  • Immuno-oncology biotech
  • Oncolytic virus therapy

Where Nouscom is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Nouscom business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Cancer Immunotherapy Development and Commercialization: Pre-revenue clinical-stage biotech company developing next-generation immunotherapies. Revenue will be generated through commercialization of approved cancer immunotherapies (NOUS-209, NOUS-PEV) upon successful clinical development and regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Nouscom product offering

Product offering

Core offering

Nouscom develops next-generation viral vectored cancer immunotherapies based on a proprietary heterologous prime/boost platform using Great Ape Adenovirus (GAd) and Modified Vaccinia Virus Ankara (MVA). Its clinical candidates include NOUS-209 (off-the-shelf immunotherapy for MSI-H/dMMR tumors and Lynch Syndrome cancer interception), NOUS-PEV (personalized neoantigen vaccine for solid tumors), and NOUS-THV-001 (targeted and armored oncolytic herpes virus), supported by the proprietary VENUS neoantigen prediction algorithm.

Product overview

Nouscom is a clinical-stage biotech company developing next-generation cancer immunotherapies based on proprietary viral vector platforms. The company's portfolio consists of three main products: NOUS-209 (an off-the-shelf immunotherapy encoding 209 shared neoantigens for MSI tumors and Lynch Syndrome cancer interception), NOUS-PEV (a personalized neoantigen vaccine tailored to individual patient tumors using the VENUS algorithm), and NOUS-THV-001 (an armored oncolytic herpes virus for solid tumors). The technology platform combines great ape adenovirus (GAd) and Modified Vaccinia Virus Ankara (MVA) vectors with bioinformatics tools for neoantigen prediction. Clinical programs span from early cancer interception in Lynch Syndrome carriers to treatment of metastatic colorectal cancer.

Differentiator

Problem solved

Functional benefit

Brands

  • NOUS-209: Off-the-shelf cancer immunotherapy encoding 209 shared frameshift peptide neoantigens for treatment of dMMR/MSI tumors and cancer interception in Lynch Syndrome carriers
  • NOUS-PEV
  • NOUS-THV-001
  • VENUS

Products and services

  • NOUS-209

Quantifiable outcome

  • 100% of evaluable participants (37/37) developed robust T cell responses against multiple neoantigens in Lynch Syndrome trial
  • +4 more outcomes

Companies that use Nouscom

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Nouscom technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

Feature6 records

Nouscom partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson Cancer Center serves as the principal investigator site for the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome carriers (NCT05078866). The trial is conducted through the iCAN-PREVENT consortium. Dr. Eduardo Vilar-Sanchez is the principal investigator.
  • National Cancer Institute (NCI)coreStrategic or Co-development PartnerThe NCI, part of the National Institutes of Health, sponsors clinical trial NCT05078866 under Award Number UG1CA242609. Activities are coordinated through the iCAN-PREVENT consortium.
  • Leuven Cancer InstitutecoreStrategic or Co-development PartnerThe Leuven Cancer Institute in Belgium served as principal investigator site for the Phase 1b trial of NOUS-PEV in solid tumors. Dr. Oliver Bechter is the principal investigator.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Nouscom competitors and assessment

Company assessment

Direct peers

  • BioNTech: Global leader in personalized neoantigen cancer vaccines (e.g., BNT122/RO7198457 with Roche) using mRNA platform. Directly comparable to Nouscom in target biology (personalized neoantigens, MSI/solid tumors) and combination-with-checkpoint-inhibitor strategy, though using a different delivery modality.
  • Moderna: Develops mRNA-4157, a personalized neoantigen cancer vaccine in Phase 3 with Merck (KEYNOTE-942). Competes head-to-head with NOUS-PEV in melanoma/NSCLC combination settings with pembrolizumab and is the dominant scale competitor in personalized cancer vaccines.
  • Gritstone bio: Develops shared-neoantigen (off-the-shelf, e.g., SLATE) and personalized (autogene cevumeran with Roche) neoantigen cancer vaccines. Highly comparable technology overlap with NOUS-209 (shared FSP antigens) and NOUS-PEV (personalized), targeting similar MSI and solid tumor indications.
  • Transgene: French clinical-stage biotech using viral vector (MVA, vaccinia, adenovirus) platforms for cancer immunotherapy, including oncolytic viruses and therapeutic vaccines. Closest direct competitor in terms of viral vector delivery technology and immuno-oncology focus.
  • Bavarian Nordic: MVA-based vaccine specialist (MVA-BN platform, JYNNEOS) now expanding into cancer immunotherapy combinations. Comparable in viral vector backbone (MVA) and potential overlap with NOUS-209 prime-boost constructs.
  • CureVac: mRNA-based cancer vaccine developer (CV8102, CV9202) with ongoing oncology programs in combination with checkpoint inhibitors and shared antigen approaches. Comparable personalized cancer vaccine peer using a different delivery platform.
  • ISA Pharmaceuticals: Clinical-stage biotech developing synthetic long peptide therapeutic cancer vaccines (e.g., ISA101b HPV) with checkpoint combinations. Directly comparable therapeutic vaccine modality targeting defined tumor antigens.
  • PsiOxus Therapeutics: Develops oncolytic virus platforms (e.g., enadenotucirev, NG-641) with immune-armoring for solid tumors. Closely comparable to NOUS-THV-001 in the oncolytic virus / TME-modulation space.

Broad incumbents

  • Merck KGaA: Operates a viral vector / MVA manufacturing platform through its Life Science and Healthcare divisions and is a major checkpoint inhibitor (avelumab) provider often used in combinations. Comparable on viral vector CMC capabilities and combination immuno-oncology positioning.
  • Amgen (Imlygic / BioVex legacy): Through Imlygic (talimogene laherparepvec), Amgen commercializes the only FDA-approved oncolytic HSV. Comparable in oncolytic herpes virus technology and armored immunomodulation strategy to NOUS-THV-001, though serving an established melanoma indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Nouscom social profiles

Digital presence

Nouscom financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nouscom leadership team

Management profile

Number of profiles

Profiles14 records

Nouscom funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nouscom M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nouscom

What does Nouscom do?

Nouscom develops next-generation viral vectored cancer immunotherapies based on a proprietary heterologous prime/boost platform using Great Ape Adenovirus (GAd) and Modified Vaccinia Virus Ankara (MVA). Its clinical candidates include NOUS-209 (off-the-shelf immunotherapy for MSI-H/dMMR tumors and Lynch Syndrome cancer interception), NOUS-PEV (personalized neoantigen vaccine for solid tumors), and NOUS-THV-001 (targeted and armored oncolytic herpes virus), supported by the proprietary VENUS neoantigen prediction algorithm.

Is Nouscom a public or private company?

Nouscom is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nouscom founded?

Nouscom was founded in 2015. It employs 51 to 100 people.

Where is Nouscom based?

Nouscom is headquartered in Basel, Switzerland, in the Europe region.

How does Nouscom make money?

One revenue line is on record: cancer Immunotherapy Development and Commercialization.

Who are Nouscom's main competitors?

Direct peers on record are BioNTech, Moderna, Gritstone bio, Transgene, Bavarian Nordic, CureVac, ISA Pharmaceuticals and PsiOxus Therapeutics. Broad incumbents are Merck KGaA and Amgen (Imlygic / BioVex legacy).

Does Nouscom have an API?

No public API is recorded for Nouscom.

What industry is Nouscom in?

Nouscom's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chExecutive reshuffles in diverse startupsLeadership changes at Nouscom, Oculus, Smart Energy Link, Rheo, and Liom include promotions and new appointments. Nouscom promoted Loredana Siani to CTO, Oculus appointed Björn Tackenberg as CSO, Smart Energy Link named Beat Scheurer CEO, Rheo appointed Guy Spörri CEO, and Liom added Vesa Mannisto as supply chain chief. These moves support growth amid positive development.Pulse 2.0Nouscom Names Loredana Siani As CTONouscom promoted Loredana Siani to Chief Technology Officer and appointed Concetta Baldo as Head of Clinical Operations. The appointments follow a €120 million Series D financing and support advancing NOUS-209 into a registration-enabling trial for Lynch syndrome.GlobeNewswireNouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology OfficerNouscom promoted Loredana Siani to Chief Technology Officer, effective November 2, 2026, to lead CMC and commercial-scale manufacturing. The move follows a €120 million Series D financing to advance NOUS-209 into a registration-enabling trial in Lynch Syndrome. Concetta Baldo was also promoted to Head of Clinical Operations.EuropaWireNeva SGR invests in Nouscom’s €120 million funding round to advance next-generation cancer immunotherapiesNeva SGR invested in Nouscom's €120 million Series D round to advance NOUS-209, a neoantigen-based immunotherapy for cancer interception in Lynch Syndrome carriers. Clinical data showed evaluable patients remained free of advanced adenomas and colorectal cancer at years one and two, with findings to be presented at ESMO.Startup ResearcherNouscom Closes Oversubscribed €120 Million Series D FinancingNouscom closed an oversubscribed €120 million Series D financing on October 19, 2026, co-led by M Ventures and Revelation Partners. Proceeds will fund a registration-enabling trial of NOUS-209 in Lynch Syndrome carriers, with long-term data showing no advanced adenomas or colorectal cancer after two years.MarketScreenerIntesa's Neva SGR invests in Nouscom's cancer biotechnologyNeva SGR, Intesa Sanpaolo's venture capital arm, invested in Nouscom, a cancer immunotherapy biotech, through its Neva II fund. The investment is part of a €120m Series D round to accelerate clinical development of NOUS-209, an off-the-shelf cancer immunotherapy for Lynch syndrome carriers. The company is based in Switzerland with Italian research and manufacturing.TechStartupsStartup Funding News Today, October 19, 2026: Tenstorrent, Nouscom, Even Healthcare, Vessla & MoreOn October 19, 2026, global startup funding saw Tenstorrent raise $1.5 billion in Series E at a $6.2 billion valuation, the day's largest round. Other notable deals included Nouscom's €120 million biotech round and Even Healthcare's $50 million Indian healthcare financing. Investors concentrated capital in AI infrastructure, biotech, and regulated industries.Startup BusinessNouscom raccoglie 120 milioni di euro per intercettare i tumoriNouscom closed a €120M Series D round co-led by M Ventures and Revelation Partners, with new investors including Angelini Industries and CDP VC. The funds will develop NOUS-209, an immunotherapy for Lynch syndrome, with long-term data showing no advanced adenomas or colon cancer after 1-2 years. The company will present these results at ESMO in Madrid in October 2026.Tech Funding NewsSwiss biotech Nouscom secures $135M, pushing cancer prevention vaccine forward — TFNNouscom raised $135M in a Series D co-led by M Ventures and Revelation Partners to fund a global trial of its NOUS-209 vaccine for Lynch syndrome carriers. The trial is registration-enabling, with early data showing immune responses in 37 of 45 participants, but no control group prevents proving prevention. The company aims to support a regulatory approval application.startupticker.chNouscom raises $135 Million to advance its cancer immunotherapyBasel-based Nouscom closed an oversubscribed $135 million Series D financing to advance its lead asset NOUS-209, an off-the-shelf cancer immunotherapy for Lynch Syndrome carriers. Phase 1b/2 data showed all evaluable carriers remained free of advanced adenomas and colorectal cancer after years 1 and 2. Proceeds will fund a registration-enabling trial, with data to be presented at ESMO.